20 countries win zero tariff on specialty pharma; 100% hits others Sept 29

For supply chain and logistics leaders, the new US tariff schedule creates a critical two-tier customs environment: zero ad valorem rates for specialty pharmaceuticals and components from 20 trade-partner countries, and 100% duties on most patented pharma imports from elsewhere starting September 29. Every bill of material, country-of-origin declaration, and trade lane now needs re-screening to capture the carve-out or avoid a prohibitive duty.

The United States has introduced a two-tier tariff framework for pharmaceutical imports. On September 29, 2026, the Commerce Department published in the Federal Register a list of 20 jurisdictions—including India, the European Union, Japan, South Korea, Switzerland, Liechtenstein, the United Kingdom, Vietnam, and several others—that will face zero ad valorem tariff on certain specialty drugs and associated ingredients used to treat rare medical conditions. Simultaneously, a 100 percent tariff on certain patented pharmaceutical imports and their associated ingredients takes effect, creating a sharp split between exempt and non-exempt supply lines.

“

The policy roots trace to a proclamation issued by President Donald Trump on April 2, 2026, which directed tariffs on imports of patented pharmaceuticals, biologics, and associated ingredients into the U.S.

The zero-rate exemption is not blanket. It covers all drugs designated for rare diseases, infertility treatments, cell therapies, gene therapies, antibody-drug conjugates (ADCs), and animal pharmaceuticals, as well as components of those products. An ad valorem tariff is defined by the World Customs Organisation as a set percentage of the monetary value of the goods to be taxed, so a 100 percent rate effectively doubles the declared value of an import for duty purposes. The carve-out therefore shields entire classes of advanced and often high-cost medicines from that increase, but only for imports originating in the listed countries.

The policy roots trace to a proclamation issued by President Donald Trump on April 2, 2026, which directed tariffs on imports of patented pharmaceuticals, biologics, and associated ingredients into the U.S. as part of a broader effort to encourage domestic production. The notice says qualifying jurisdictions receive the zero percent rate because they have a current or forthcoming trade and security framework agreement with the U.S. That geopolitical criterion means the exemption is as much about bilateral alignment as it is about therapeutic need. For countries without such an agreement, the baseline 100 percent tariff applies, regardless of whether their exports are economically competitive.

For multinational pharmaceutical supply chains, the new rules introduce significant classification and compliance burden. Importers must determine whether a product falls within the eligible categories—rare disease, infertility, cell, gene, ADC, or animal pharmaceutical—and whether its components qualify for the same zero rate. Country of origin becomes decisive: identical specialty products may receive zero duty if shipped from India, Switzerland, or the EU, but 100 percent duty if shipped from other manufacturing hubs not on the list. This may accelerate a reallocation of third-party manufacturing, fill-finish operations, and component sourcing toward the 20 exempt jurisdictions, while complicating logistics for manufacturers with mixed-country supply chains.

For patients and health systems, the zero-rate list may blunt some cost pressures for advanced therapies, which are frequently imported from specialized facilities in listed countries. The inclusion of components is notable because cell and gene therapy manufacturing relies on globally sourced plasmids, viral vectors, reagents, and consumables; a 100 percent tariff on those inputs could have cascaded into higher development and treatment costs. By exempting components alongside final products, the policy reduces the risk of immediate price spikes in the rare-disease and advanced-therapy segments. However, the broader 100 percent tariff on patented pharmaceuticals could still raise costs for many branded medicines not covered by the exemption, potentially flowing through to insurers, providers, and patients over time.